Having trouble accessing articles? Reset your cache.

3Q approvals

3Q approvals

Company Approval
Abraxis BioScience Inc. (NASDAQ:ABII)/ Otsuka Pharmaceutical Co. Ltd. (Tokyo:4768) Japan approves Abraxane nab-paclitaxel to treat breast cancer
Allergan Inc. (NYSE:AGN) EC approves Ozurdex dexamethasone intravitreal implant to treat macular edema following retinal vein occlusion
Allergan Inc. (NYSE:AGN) FDA approves Ozurdex dexamethasone intravitreal implant to treat non-infectious uveitis affecting the posterior segment of the eye
Baxter International Inc. (NYSE:BAX) Austria approves PreFluCel seasonal influenza vaccine
Biota Holdings Ltd. (ASX:BTA)/Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) Japan approves Inavir laninamivir dry powder inhaler to treat influenza A and B in adults and children
Celgene Corp. (NASDAQ:CELG) Japan approves Revlimid lenalidomide to treat myelodysplastic syndromes (MDS) in patients with 5q chromosomal deletion
Forest Laboratories Inc. (NYSE:FRX)/ Nycomed EC approves Daxas roflumilast for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis
Kamada Ltd. (Tel Aviv:KMDA) FDA approves Glassia to treat alpha 1-antitrypsin (AAT) deficiency
Merck & Co. Inc. (NYSE:MRK) EC, Iceland and Norway approve Brinavess IV vernakalant for converting recent onset atrial fibrillation (AF) to sinus rhythm in adults
Merck & Co. Inc. (NYSE:MRK) EC approves Sycrest asenapine to

Read the full 2041 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers